GSK Australia Reports 2012 Results to ASIC

GlaxoSmithKline (GSK) reported to the Australian Securities and Investment Commission (ASIC) for 2012 sales of $1,452m and a total profit before tax of $41m.

14/05/2013

GSK and Save the Children form unique partnership to save the lives of one million children

An ambitious new partnership to save the lives of a million of the poorest children in the world has been launched by GSK and Save the Children.

14/05/2013

Nominations Open for GSK Award for Research Excellence

Now in its 33rd year, the ARE is one of the most prestigious awards available to the Australian research community. The annual Award and accompanying grant of $80,000, recognises outstanding achievement in medical research and facilitates career...

30/04/2013

Trial seeks sexually active men 50+. Aims to test sexual function. Must have enlarged prostate.

Australian hospitals are recruiting men aged over 50 into a unique global clinical trial that aims to assess the impact on sexual function of medicines used to reduce the size of the prostate.

18/04/2013

GSK discloses 2012 payments to Australian healthcare professionals

As part GlaxoSmithKline’s (GSK) ongoing commitment to increase transparency, we are disclosing today, the aggregate amount of fees paid to Australian healthcare professionals and health-related organisations for all sponsorships, grants, speaking...

28/03/2013

Fluarix® Product Notification

GlaxoSmithKline Australia (GSK) in consultation with the Therapeutic Goods Administration (TGA) has issued a product notification to healthcare professionals for its influenza vaccine Fluarix (Inactivated Split Influenza Vaccine).

06/03/2013

GSK’s response to the public roundtable report on Arachnoiditis

GlaxoSmithKline (GSK) has reviewed the final report of the House of Representatives Standing Committee on Health and Ageing into adhesive arachnoiditis (“Living with the pain of adhesive arachnoiditis”).

04/03/2013

Report on the Public roundtable into Adhesive Arachnoiditis

GlaxoSmithKline (GSK) welcomes the report on the roundtable into adhesive arachnoiditis provided by the Standing Committee on Health and Ageing released today.

12/02/2013

GSK Australia divestment of Kapanol Complete

GSK Australia’s divestment of the pain relief product Kapanol (morphine sulphate) to Mayne Pharma Group Limited (Mayne Pharma) was finalised today.

01/02/2013

Voluntary recall - ten batches of Ventolin and Asmol Inhalers

GlaxoSmithKline (GSK) is initiating a retail level recall of 10 batches of Ventolin and Asmol Inhalers due to a fault in the delivery mechanism leading to an inconsistent dose.

24/12/2012